Vitafoods Europe

Aquanova, a company specializing in enhancing biovailability of natural compounds, will discuss its latest research on NovaSOL Astaxanthin, which found that the specialty ingredient was more bioavailable than the native form of astaxanthin. The findings were published in the European Journal of Drug Metabolism and Pharmacokinetics.
 
NovaSol technology creates a micelle structure similar to those found in nature, surrounding the active components. Astaxanthin is highly lipophilic with low oral bioavailability, and is an expensive ingredient, creating a pressing need for low-dose, highly-absorbable forms of the compound.
 
The Aquanova study compared the pharmacokinetic properties of the novel astaxanthin preparation versus standard astaxanthin in 400 mg capsules after a single oral dose administration to 12 healthy male adults. The test and reference astaxanthin were administered in a crossover design, with a washout period of a week in between. Blood samples were collected at hourly intervals for the first 12 hours, then at 24, 48, and 72 hours after administration.
 
“The micellar formulation of astaxanthin was capable of producing a high concentration of astaxanthin in plasma in a shorter period of time, which is therefore expected to provide faster potential for therapeutic efficacy,” the authors of the study concluded.
 
“Get more with less,” said Frank Benham, CEO. “Our goal is to provide the most efficacious dose as efficiently as possible and our NovaSol ingredient portfolio is a testament to that. Aquanova gives formulators the confidence they need when incorporating branded ingredients like NovaSol Astaxanthin and NovaSol curcumin in finished products.”
 
Further research conducted by a French institute, which will focus on the ingredient’s effects on skin health, is already underway, with results expected in 2024.
 
Prior research on NovaSol technology found that it increased curcumin’s bioavailability by 57-fold compared to commercially available preparations.